Kaye Biotech Inc. had the following equity account balances at December $31,2022$:

Preferred shares, $$2\mathrm{.}95,$ non$-$cumulative,

Authorized: $22,000$ shares

Issued and outstanding: $6,000$ shares $ $42,000$

Common shares,

Authorized: Unlimited

Issued and outstanding: $90,000$ shares $304,618$

Retained earnings $44,600$

On February $1,2023,6,000$ preferred shares were issued at $$8\mathrm{.}70$ each. The board of directors declared and paid the annual cash dividend on the preferred shares on June $30,2023,$ and a $13\%$ common share dividend was declared and distributed on the same day when the market price per common share was $$4\mathrm{.}70.$ On October $1,2023,22,000$ common shares were issued at $$4\mathrm{.}84$ each. Profit earned during $2023$ was $$418,800.$

Required:

Using the information provided, prepare the statement of changes in equity for the year ended December $31,2023.($Amounts to be deducted should be indicated by a minus sign.$)$